ITMCTR2100004410
Recruiting
未知
A multi-center, randomized, controlled, double-blind clinical study on the treatment of Chronic kidney disease with Kidney-Yang deficiency syndrome by Wenshenyang prescription
Beijing University of Chinese Medicine0 sitesTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Beijing University of Chinese Medicine
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Volunteer to participate in the clinical trial and sign the informed consent;
- •2\. Subjects meeting the diagnostic criteria of chronic kidney disease;
- •3\. Patients with nephrotic syndrome, chronic nephritis syndrome, diabetic nephropathy, IgA nephropathy, membranous nephropathy, focal segmental sclerosing glomerulonephritis, etc;
- •4\. EGFR \> 29ml / (min · 1\.73m2\) in patients with chronic kidney disease (CKD) stage 1\-3;
- •5\. Patients with kidney yang deficiency syndrome in TCM;
- •6\. Patients aged 18\-75 years old, regardless of gender.
Exclusion Criteria
- •1\. Patients with acute kidney injury in recent one month;
- •2\. Patients with acute infectious diseases, active or delayed chronic hepatitis B, decompensated cirrhosis and active tuberculosis;
- •3\. Patients with serious cardiovascular and cerebrovascular diseases, lung and liver diseases and other primary diseases, or mental diseases;
- •4\. Patients with unstable vital signs and severe electrolyte disorder, or have received renal replacement therapy;
- •5\. Patients with active gastrointestinal bleeding, severe thrombocytopenia, coagulation dysfunction and other hematological diseases in recent 3 months;
- •6\. Patients with other diseases requiring long\-term use of other traditional Chinese medicine preparations for more than 4 weeks;
- •7\. Those patients whose aspartate aminotransferase and alanine aminotransferase are 1\.5 times higher than the normal value;
- •8\. Pregnant women, lactating women or women with pregnancy plans in the near future;
- •9\. Those subjects with allergic constitution are known or suspected to be allergic to the test drug and its excipients;
- •10\. Subjects who have participated in or are participating in other clinical trials in recent 3 months;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (PeproStat) to stop bleeding during surgery.To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or suturesor are inappropriate.MedDRA version: 20.0Level: LLTClassification code 10053001Term: Surgical haemostasisSystem Organ Class: 100000004865Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]EUCTR2016-003661-26-HRHaemostatix Ltd300
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (PeproStat) to stop bleeding during surgery.To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or suturesor are inappropriate.MedDRA version: 19.0 Level: LLT Classification code 10053001 Term: Surgical haemostasis System Organ Class: 100000004865Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]EUCTR2016-003661-26-GBHaemostatix Ltd214
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (PeproStat) to stop bleeding during surgery.To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or suturesor are inappropriate.MedDRA version: 20.0Level: LLTClassification code 10053001Term: Surgical haemostasisSystem Organ Class: 100000072483Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]EUCTR2016-003661-26-PLHaemostatix Ltd300
Active, not recruiting
Phase 1
A multicenter, randomised, controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with clinically relevant grass pollen sensitivity in comparison to a symptomatic standard treatment with add on placeboIgE-mediated allergic disease manifested as symptoms of allergic rhinitis/rhinoconjunctivitis with or without allergic bronchial asthma (GINA I and II), triggered by grass pollen allergens.MedDRA version: 9.1Level: LLTClassification code 10036019Term: Pollen allergyEUCTR2006-005911-82-PLAllergopharma Joachim Ganzer KG230
Completed
Not Applicable
Anakinra in the treatment of acute calcium pyrophosphate arthritisISRCTN46471047niversity Hospital Centre and University of Lausanne (CHUV) (Switzerland)-Service of Rheumatology75